Fenwick is representing Pixium Vision (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, in its definitive business combination agreement with Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals. Pixium Vision will, following the contribution to Second Sight of all of its assets and liabilities in relation to its neuromodulation technology used in the treatment of blindness, become the controlling shareholder of the new combined company, owning 60% of the total equity before a capital raise. The combined company will focus on retinal stimulation through the Prima System.
More information about the transaction is available through Pixium Vision’s announcement.
The Fenwick transaction team includes corporate partner Robert Freedman and David Michaels and associates Ryan Mitteness, Kee Bong Kim, Lailey Rezai and Joshua Fuller; as well as technology transactions partner Stefano Quintini and counsel Amy Manning.